Patients with mild Alzheimers disease who took Eli Lilly and Cos experimental drug solanezumab early in the course of their disease preserved more of their cognitive and functional ability, according to new Lilly data released on 22 July.
Jul 23, 2015
- Reliance to sell 25% in refining business to Aramco to pare Rs 3 lakh crore debt?
- SpiceJet to give hiring preference to employees of Jet Airways: Chairman
- Jet Airways to temporarily shut operations tonight, last flight at 10.30 pm
- Jet Airways lenders may be facing dilemma of writing off 80% dues or losing 100% loans
- Is Air India skidding down the same road that Jet and Kingfisher took?